Clinical practice guideline for stage Ⅳ primary lung cancer in China (2023 edition) / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 1-30, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-969801
ABSTRACT
Primary lung cancer is the most common malignant disease and the leading cause of cancer death in China, with an estimated 828 thousand incident cases and 657 thousand deaths in 2016. Due to the absence of effective early screening methods, most patients with lung cancer are in stage Ⅳ when diagnosed. Multi-disciplinary treatment based on systemic therapy is the treatment principle for patients with stage Ⅳ lung cancer, chemotherapy is the cornerstone of stage Ⅳ lung cancer, but its efficacy is unsatisfactory. In recent years, with the rapid development of molecular targeted therapy and immunotherapy, the treatment concept has continuously changed and treatment outcome for patients has also been greatly improved. In order to update the progress in the treatment of stage Ⅳ lung cancer worldwide timely, and further improve the level of standardized diagnosis and treatment of stage Ⅳ lung cancer in China, Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to compose "Clinical Practice Guideline for Stage Ⅳ Primary Lung Cancer in China (2023 edition)" .
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
China
/
Terapia Molecular Dirigida
/
Inmunoterapia
/
Neoplasias Pulmonares
/
Oncología Médica
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS